Pharmaceutical Research
Pioneering advancements in medical science.
Built around the business reality of your team.
Pharmaceutical innovation moves at the speed of trust. Health systems, payers, and regulators demand reproducible science, transparent data, and ethical sourcing — not just bold ideas. Future Trity Pharma's research division exists to compress the gap between molecular discovery and patient outcome without compromising the standards that protect them.
Most pipelines stall between target validation and IND-enabling studies. Fragmented data, inconsistent assay protocols, and weak translational signals burn capital and time. We solve this with an integrated research-to-clinic operating model.
A method, not just a capability.
Target identification grounded in real-world evidence and proteomics.
GLP-aligned preclinical workflows with end-to-end audit trails.
Translational biomarker discovery to de-risk Phase I readouts.
Open collaboration with academic centres and contract research partners.
Clear deliverables, audit-ready documentation.
Discovery Programs
High-throughput screening, structure-activity relationship modeling, and lead optimisation.
Preclinical Studies
In vitro and in vivo pharmacology, ADME, toxicology, and formulation development.
Regulatory Dossiers
IND, IMPD, and CTA-ready packages aligned to FDA, EMA, and PMDA expectations.
Translational Science
Biomarker strategy, companion diagnostics, and patient stratification frameworks.
The difference is in the discipline.
Scientific Depth
Cross-disciplinary teams across medicinal chemistry, biology, and clinical pharmacology.
Regulatory Fluency
Embedded regulatory affairs from day one — no costly retrofits before submission.
Operational Integrity
ISO 9001, GLP, and GxP-aligned governance with full data traceability.
Speed With Rigour
Parallelised workflows shorten discovery timelines without inflating study risk.
Bring us your molecule, indication, or therapeutic question — we'll show you a path to clinic.
Our team responds within one business day with a tailored capability brief and next-step proposal.
Brief our Pharmaceutical Research team.
Submissions are reviewed by the capability lead within one business day. All information is treated as confidential under our standard Mutual NDA framework.
Capability lead acknowledges within 24 business hours with a reference number.
Mutual NDA executed prior to detailed technical exchange.
Scoping call with subject-matter experts and a written capability brief.